Oral Antidiabetic Drugs Market Report 2026

Oral Antidiabetic Drugs Market Overview

• Oral Antidiabetic Drugs market size has reached to $66.73 billion in 2025 • Expected to grow to $92.64 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Surge In Type 2 Diabetes Fueling The Growth Of The Market Due To Rising Obesity-induced Insulin Resistance • Market Trend: Innovative Oral Medications Promise Improved Therapeutic Benefits And Accessibility • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oral Antidiabetic Drugs Market?

Oral antidiabetic drugs refer to a class of medications taken by mouth to help manage and control blood glucose levels in individuals with type 2 diabetes. These drugs work through various mechanisms such as increasing insulin sensitivity, stimulating insulin secretion, or reducing glucose production in the liver. They are essential in diabetes treatment to prevent complications and maintain long-term health. The main drug classes of oral antidiabetic drugs include biguanides, dipeptidyl peptidase-4 inhibitors, sodium glucose transport protein-2 inhibitors, sulfonylureas, thiazolidinediones, megalitinides, alpha glucosidase inhibitors, and others. Biguanides refer to a class of oral antidiabetic drugs that lower blood glucose levels primarily by reducing hepatic glucose production and improving insulin sensitivity. The routes of administration are oral, sublingual, and buccal, and the various therapeutic areas are type 2 diabetes, gestational diabetes, and type 1 diabetes. The multiple distribution channels are hospital pharmacies, retail pharmacies, online pharmacies, and others, and key end users such as hospitals, pharmact store, drug stores, diabetes treatment centers, and others.

What Is The Oral Antidiabetic Drugs Market Growth Forecast?

The oral antidiabetic drugs market size is expected to see strong growth in the next few years. It will grow to $92.64 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to development of novel dpp-4 inhibitors and sglt2 inhibitors, expansion of combination therapies, increasing adoption of personalized medicine approaches, growth of online pharmacy and telemedicine channels, rising government initiatives for diabetes care. Major trends in the forecast period include rising prevalence of type 2 diabetes, increasing adoption of combination oral antidiabetic drugs, expansion of online and retail pharmacy channels, growing focus on personalized diabetes management, enhanced awareness and education on diabetes care.

Global Oral Antidiabetic Drugs Market Segmentation

1) By Drug Class: Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes 2) By Route Of Administration: Oral, Sublingual, Buccal 3) By Therapeutic Area: Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels 5) By End User: Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users Subsegments: 1) By Biguanides: Metformin Hydrochloride, Metformin Extended Release, Combination Products 2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin 3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin 4) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide 5) By Thiazolidinediones: Pioglitazone, Rosiglitazone 6) By Meglitinides: Repaglinide, Nateglinide 7) By Alpha Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose 8) By Other Drug Classes: Bromocriptine, Colesevelam

What Is The Driver Of The Oral Antidiabetic Drugs Market?

The increasing type 2 diabetes is expected to propel the growth of the oral antidiabetic drugs market going forward. Type 2 diabetes refers to a chronic condition where the body either resists insulin or doesn't produce enough to maintain normal glucose levels. The rise in type 2 diabetes is due to the increasing obesity rates, as excess body fat results to insulin resistance and impaired glucose regulation. Oral antidiabetic drugs help manage type 2 diabetes by improving insulin sensitivity, enhancing insulin secretion, or reducing glucose production and absorption, thereby maintaining optimal blood sugar levels. For instance, in March 2025, according to the Office for Health Improvement and Disparities, a UK-based government agency, reported that type 2 diabetes prevalence in adults aged 17+ in England rose to 7.0%, up from 6.8% in March 2023. Therefore, increasing type 2 diabetes is propelling growth of the oral antidiabetic drugs industry.

Key Players In The Global Oral Antidiabetic Drugs Market

Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited

Global Oral Antidiabetic Drugs Market Trends and Insights

Major companies operating in the oral antidiabetic drugs market are focusing on clinical trials to develop more effective and safer treatment options, expand their product portfolios, and gain regulatory approvals for next-generation therapies. Clinical trials are controlled research studies conducted on human participants to evaluate the safety, effectiveness, and side effects of new medical treatments, drugs, or interventions. For instance, in April 2025, Eli Lilly and Company, a US-based pharmaceutical company, introduced Orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist designed to simplify diabetes management through successful phase 3 trial. This oral therapy aims to deliver comparable efficacy and safety to injectable options while enhancing patient adherence. In clinical trials, orforglipron lowered HbA1c (a marker of blood sugar control) by an average of 1.3% to 1.6% across different doses over 40 weeks.

What Are Latest Mergers And Acquisitions In The Oral Antidiabetic Drugs Market?

In January 2024, Roche Group, a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics Inc., for an undisclosed amount. With this acquisition, Roche aimed to strengthen its pipeline in obesity and diabetes treatments by gaining access to Carmot Therapeutics' innovative small-molecule therapeutics targeting incretin biology. Carmot Therapeutics is a US-based company that is developing oral antidiabetic drugs, including CT-996, a once-daily oral small molecule GLP-1 receptor agonist.

Regional Insights

North America was the largest region in the oral antidiabetic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oral Antidiabetic Drugs Market?

The oral antidiabetic drugs market consists of sales of dual or combination oral therapies, glucokinase activators, and amylin analogs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oral Antidiabetic Drugs Market Report 2026?

The oral antidiabetic drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral antidiabetic drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.